Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 2/20 | 0.95 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.95 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.95 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | EYA2 | O00167 | 1/20 | 0.59 |
| ▸ | APP | P05067 | 1/20 | 0.59 |
| ▸ | ACE | P12821 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | DRD1 | P21728 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Egtazic Acid SCHEMBL831877 | 1.00 | BLM (0.95) | BLMPMP22HSD17B10TDP1EYA2 | |
| Egtazic Acid SCHEMBL456238 | 1.00 | BLM (0.95) | BLMPMP22HSD17B10TDP1EYA2 | |
| Egtazic Acid SCHEMBL3042159 | 1.00 | BLM (0.95) | BLMPMP22HSD17B10TDP1EYA2 | |
| Egtazic Acid SCHEMBL920203 | 0.98 | BLM (1.00) | BLMPMP22HSD17B10TDP1EYA2 | |
| SCHEMBL11684972 | 0.98 | BLM (1.00) | BLMPMP22HSD17B10TDP1EYA2 | |
| Egtazic Acid SCHEMBL22901 | 0.98 | BLM (1.00) | BLMPMP22HSD17B10TDP1EYA2 | |
| Egtazic Acid SCHEMBL23859106 | 0.95 | BLM (0.95) | BLMPMP22HSD17B10TDP1EYA2 | |
| Egtazic Acid SCHEMBL5067266 | 0.95 | BLM (0.95) | BLMPMP22HSD17B10TDP1EYA2 | |
| Egtazic Acid SCHEMBL7541607 | 0.95 | BLM (0.95) | BLMPMP22HSD17B10TDP1EYA2 | |
| Egtazic Acid SCHEMBL15413556 | 0.95 | BLM (0.95) | BLMPMP22HSD17B10TDP1EYA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241044-A1 | TREATMENT FOR PSORIASIS AND SKIN INFLAMMATORY DISEASES | ZYDUS LIFESCIENCES LIMITED (IN) | 2023-08-03 | — | — | US | claimed |
| EP-4157233-A1 | TREATMENT FOR PSORIASIS AND SKIN INFLAMMATORY DISEASES | Zydus Lifesciences Limited (IN) | 2023-04-05 | — | — | EP | claimed |
| CN-115666539-A | Treatment of psoriasis and skin inflammatory diseases | 兹杜斯生命科学有限公司 | 2023-01-31 | — | — | CN | claimed |
| WO-2022238745-A1 | TOPICAL PHARMACEUTICAL COMPOSITION OF HIF PROLYL HYDROXYLASE INHIBITORS | ZYDUS LIFESCIENCES LIMITED (IN) | 2022-11-17 | — | — | WO | claimed |
| WO-2021240454-A1 | TREATMENT FOR PSORIASIS AND SKIN INFLAMMATORY DISEASES | CADILA HEALTHCARE LIMITED (IN) | 2021-12-02 | — | — | WO | claimed |
| EP-0743519-B1 | Improved method and reagent composition for performing leukocyte differential counts on fresh and aged whole blood samples, based on intrinsic peroxidase activity of leukocytes | BAYER AG (US) | 2002-08-28 | — | — | EP | claimed |
| US-20240238189-A1 | TOPICAL SKIN CARE FORMULATIONS COMPRISING PLANT EXTRACTS | MARY KAY INC. | 2024-07-18 | — | — | US | disclosed |
| US-11992550-B2 | Topical skin care formulations comprising plant extracts | MARY KAY INC. (US) | 2024-05-28 | — | — | US | disclosed |
| US-20240094222-A1 | Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) Biomarkers and Uses Thereof | SomaLogic Operating Co, Inc. (US) | 2024-03-21 | — | — | US | disclosed |
| US-20240050357-A1 | TOPICAL SKIN CARE FORMULATIONS COMPRISING PLANT EXTRACTS | MARY KAY INC. | 2024-02-15 | — | — | US | disclosed |
| US-20240042244-A1 | TOPICAL SKIN CARE FORMULATIONS COMPRISING PLANT EXTRACTS | MARY KAY INC. | 2024-02-08 | — | — | US | disclosed |
| US-11890369-B2 | Topical skin care formulations comprising plant extracts | MARY KAY INC. (US) | 2024-02-06 | — | — | US | disclosed |
| WO-2024015486-A1 | METHODS FOR SAMPLE QUALITY ASSESSMENT | SOMALOGIC OPERATING CO., INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| US-8137714-B2 | Compositions comprising docynia delavajy extract and/or Elaeagnus lancelotus extract | MARY KAY INC. (US) | 2012-03-20 | — | — | US | disclosed |
| WO-2012033634-A2 | TOPICAL SKIN CARE FORMULATIONS COMPRISING PLANT EXTRACTS | MARY KAY INC. (US) | 2012-03-15 | — | — | WO | disclosed |
| US-20110189322-A1 | COMPOSITIONS COMPRISING DOCYNIA DELAVAJY EXTRACT AND/OR ELAEAGNUS LANCELOTUS EXTRACT | MARY KAY INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110086116-A1 | TOPICAL SKIN FORMULATIONS COMPRISING PLANT EXTRACTS | MARY KAY INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-20110052737-A1 | TOPICAL SKIN FORMULATIONS COMPRISING BOTANICAL EXTRACTS | MARY KAY INC. (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110044920-A1 | TOPICAL SKIN CARE FORMULATIONS | MARY KAY INC. (US) | 2011-02-24 | — | — | US | disclosed |
| WO-2010011997-A2 | COMPOSITIONS COMPRISING DOCYNIA DELAVAJY EXTRACT AND/OR ELAEAGNUS LANCELOTUS EXTRACT | MARY KAY INC. (US) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230241044-A1 | TREATMENT FOR PSORIASIS AND SKIN INFLAMMATORY DISEASES | P4HA1, PAH, TNF | BLM 4828/4885PMP22 1378/4885HSD17B10 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.